Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Simply Wall St.02-28 21:31

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614908812?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-28 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614908812","market":"sg","top_or_hot":-1,"title":"Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story","media":"Simply Wall St.","content":"<div>\n<p>Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/ionis-fda-and-phase-3-updates-reframe-rare-disease-valuation\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/ionis-fda-and-phase-3-updates-reframe-rare-disease-valuation><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/ionis-fda-and-phase-3-updates-reframe-rare-disease-valuation\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/ionis-fda-and-phase-3-updates-reframe-rare-disease-valuation","article_id":"2614908812","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/ionis-fda-and-phase-3-updates-reframe-rare-disease-valuation","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614908812","pubTimestamp":1772285471,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline.\nNew Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum.\nThese developments focus on two rare disease programs that are central to Ionis’s drug development efforts.\n\nIonis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"Ionis FDA和3期更新重塑罕见病估值故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts.  Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that targets serious, often rare conditions where treatment options can be limited. The FDA Priority Review for olezarsen and the upcoming Phase 3 data presentations for DAWNZERA come at a time when rare disease therapies and RNA based approaches remain a key area of interest for healthcare investors and larger drug developers. For you as an investor, these updates matter because they touch both regulatory progress and late stage clinical data for programs that are close to potential commercialization decisions. The way the FDA review for olezarsen and the reception of DAWNZERA Phase 3 analyses evolve over the coming months could influence how investors view Ionis’s pipeline risk profile and future revenue mix, even before any final decisions or launches occur. Stay updated on the most important news stories for Ionis Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ionis Pharmaceuticals. NasdaqGS:IONS Earnings & Revenue Growth as at Feb 2026 2 things going right for Ionis Pharmaceuticals that this headline doesn't cover. AdvertisementInvestor Checklist: How This News Frames Ionis Right Now Quick Assessment  ⚖️ Price vs Analyst Target: At US$81.15 versus a consensus target of about US$93.76, the stock sits roughly 13% below analyst expectations. ✅ Simply Wall St Valuation: Simply Wall St estimates the shares trade about 63% below its fair value, which points to a wide valuation gap. ❌ Recent Momentum: The 30 day return of about 0.94% decline shows the market has not recently rewarded the shares despite the news.  There is only one way to know the right time to buy, sell or hold Ionis Pharmaceuticals. Head to Simply Wall St's\ncompany report for the latest analysis of Ionis Pharmaceuticals's Fair Value. Key Considerations  📊 Priority Review for olezarsen and new Phase 3 data for DAWNZERA both focus on late stage, rare disease candidates that could be important to Ionis’s future revenue mix. 📊 Keep an eye on FDA review milestones, Phase 3 readouts, and how the share price behaves around the US$93.76 analyst target and Simply Wall St’s fair value estimate. ⚠️ Recent insider selling flagged as a risk may matter more if regulatory or clinical updates fall short of expectations.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Ionis Pharmaceuticals analysis. Alternatively, you can visit the\ncommunity page for Ionis Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614908812","isCrawlerRequest":true}